0001628280-26-015155
SEC filingTriSalus Life Sciences, Inc. reported Q4 2025 net sales of $13.2 million, up 60% year-over-year, and full-year 2025 revenue of $45.2 million, up 53%, exceeding prior guidance. The company reaffirmed 2026 revenue guidance of $60-62 million and raised $46 million in gross proceeds from a recent public offering.